

1 **Title:**

2 Multi-omics analysis reveals regime shifts in the gastrointestinal ecosystem in  
3 chickens following anticoccidial vaccination and *Eimeria tenella* challenge

4

5 **Authors:**

6 Po-Yu Liu (ORCID ID: 0000-0003-1290-0850)<sup>1,2,3</sup>, Janie Liaw<sup>4</sup>, Francesca Souter<sup>5</sup>, José  
7 Jaramillo Ortiz<sup>1,6</sup>, Fiona M. Tomley (ORCID ID: 0000-0003-2188-8013)<sup>1</sup>, Dirk Werling  
8 (ORCID ID: 0000-0001-5411-4044)<sup>1,6</sup>, Ozan Gundogdu (ORCID ID: 0000-0002-3550-  
9 0545)<sup>4</sup>, Damer P. Blake (ORCID ID: 0000-0003-1077-2306)<sup>1,6</sup>, Dong Xia (ORCID ID:  
10 0000-0003-4571-2776)<sup>1,\*</sup>

11

12 <sup>1</sup>Pathobiology and Population Sciences, Royal Veterinary College, Hawkshead Lane,  
13 North Mymms AL9 7TA, UK

14 <sup>2</sup>School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung  
15 804201, Taiwan

16 <sup>3</sup>Department of Biomedical Science and Environmental Biology, Kaohsiung Medical  
17 University, Kaohsiung 807378, Taiwan

18 <sup>4</sup>Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical  
19 Medicine, London, WC1E 7HT, UK

20 <sup>5</sup>Scotland's Rural College, Edinburgh, EH25 9RG, UK

21 <sup>6</sup>Centre for Vaccinology and Regenerative Medicine, Royal Veterinary College,  
22 Hawkshead Lane, North Mymms, AL9 7TA, UK

23

24

25

26 **\*Corresponding author:**

27 **Dong Xia**

28 Pathobiology and Population Sciences, Royal Veterinary College, Hawkshead Lane,  
29 North Mymms AL9 7TA, UK

30 E-mail: dxia@rvc.ac.uk

31

32

33 **ABSTRACT**

34 Coccidiosis, caused by *Eimeria* parasites, poses significant economic and welfare  
35 challenges in poultry farming. Beyond its direct impact on health, *Eimeria* infection  
36 disrupts enteric microbial populations leading to dysbiosis and increases vulnerability  
37 to secondary diseases such as necrotic enteritis, caused by *Clostridium perfringens*.  
38 The impact of *Eimeria* infection or anticoccidial vaccination on host gastrointestinal  
39 phenotypes and enteric microbiota remains understudied. In this study, the  
40 metabolomic profiles and microbiota composition of chicken caecal tissue and  
41 contents were evaluated concurrently during a controlled experimental vaccination  
42 and challenge trial. Cobb500 broilers were vaccinated with a *Saccharomyces*  
43 *cerevisiae*-vectored anticoccidial vaccine and challenged with 15,000 *Eimeria tenella*  
44 oocysts. Assessment of caecal pathology and quantification of parasite load revealed  
45 correlations with alterations to caecal microbiota and host metabolome linked to  
46 infection and vaccination status. Infection heightened microbiota richness with  
47 increases in potentially pathogenic species, while vaccination elevated beneficial  
48 *Bifidobacterium*. Using a multi-omics factor analysis (MOFA) machine learning model,  
49 data on caecal microbiota and host metabolome were integrated and distinct profiles  
50 for healthy, infected, and recovering chickens were identified. Healthy and recovering  
51 chickens exhibited higher vitamin B metabolism linked to short-chain fatty acid-  
52 producing bacteria, whereas essential amino acid and cell membrane lipid  
53 metabolisms were prominent in infected and vaccinated chickens. Notably,  
54 vaccinated chickens showed distinct metabolites related to the enrichment of  
55 sphingolipids, important components of nerve cells and cell membranes. Our  
56 integrated multi-omics model revealed latent biomarkers indicative of vaccination  
57 and infection status, offering potential tools for diagnosing infection, monitoring  
58 vaccination efficacy, and guiding the development of novel treatments or controls.

59

60 **Keywords:** *Eimeria*, yeast-based anticoccidial vaccine, gut microbiota, metabolome,  
61 multi-omics

62

63 **INTRODUCTION**

64 Protozoan parasites of the genus *Eimeria* cause coccidiosis in poultry and costs  
65 to the industry have been estimated to exceed £10 billion annually [1]. Clinical  
66 coccidiosis manifests as poor body weight gain and feed conversion with diarrhoea,  
67 bloody droppings, and mortality in severe cases. Infection induces strong pro- and  
68 anti-inflammatory cytokine responses that may exacerbate pathology [2-5]. Clinical  
69 coccidiosis is commonly avoided through a combination of good husbandry, parasite  
70 chemoprophylaxis with anticoccidial drugs and/or vaccination using varied  
71 formulations of live parasites [6, 7]. In some countries, public concern related to  
72 pathogen drug resistance and widespread use of antimicrobials in animal production  
73 are driving legislative and commercial changes, including increased use of  
74 anticoccidial vaccination [8]. Although current live parasite vaccines are effective,  
75 considerable efforts are also being made to develop recombinant anticoccidial  
76 vaccines [9]. In a previous study, a novel prototype inactivated yeast-based  
77 recombinant oral vaccine for *Eimeria tenella* was shown to result in reduced parasite  
78 replication, reduced caecal pathology and improved chicken performance compared  
79 to controls [10]. Using *Saccharomyces cerevisiae* to express and deliver *E. tenella*  
80 antigens apical membrane antigen 1 (EtAMA1) [11], immune mapped protein 1  
81 (EtIMP1) [12] and repeat 3 from microneme protein 3 (EtMIC3) [13] induced  
82 significant protection against high-level challenge in vaccinated Cobb500 broiler  
83 chickens [10]. However, the impact of vaccination and subsequent parasite challenge  
84 on the host gut and its enteric microbiota was not evaluated. Oral administration of  
85 heat-inactivated and freeze-dried *S. cerevisiae* has previously been shown to  
86 ameliorate the effects of coccidiosis in broiler chickens while modulating the host  
87 immune response and microbiota [14, 15]. Understanding the influence of a yeast-  
88 vectored anticoccidial vaccine on host metabolome and microbiomes could therefore  
89 be used to inform future vaccine development.

90 Enteric microbiomes play crucial roles in shaping host physiological functions  
91 including provision of nutrients [16, 17], immune system maturation and regulation  
92 [18, 19]. *Eimeria* infection can cause imbalance in gastrointestinal ecosystems [20,  
93 21], commonly referred to as dysbiosis, and raises the risk of enteric comorbidities  
94 such as necrotic enteritis caused by *Clostridium perfringens* [22]. Variation in the  
95 severity of damage caused by *Eimeria* infection has also been shown to associate  
96 with differences in enteric microbiomes. For example, high level caecal lesion scores  
97 recorded during *E. tenella* infection correlated with increased *Enterobacteriaceae*  
98 occurrence but decreased *Bacillales* and *Lactobacillales* [21]. However, little is known  
99 about physiological responses in gastrointestinal molecular and biochemical  
100 mechanisms, or variation in microbiota between immunologically naïve, infected and

101 vaccinated chickens. Few studies have provided insight into chickens' metabolic  
102 responses to infection or vaccination. Using an untargeted metabolomic profile  
103 assessment, Aggrey et al. (2019) found that carnitine-derived metabolites involved in  
104 fatty acid metabolism, and thromboxane B2, 12-HHTrE and itaconate involved in  
105 inflammatory responses, were influenced by *Eimeria acervulina* infection [23]. In the  
106 same way, a human shingles vaccine trial revealed that key metabolites such as sterol  
107 class metabolites, arachidonic acids, phosphoinositide, and diacylglycerol, were  
108 essential to immune signalling [24]. Here, we have created a multi-omics dataset  
109 defining caecal microbial populations (lumen contents and tissue-associated) and  
110 caecal tissue metabolomes using high-throughput sequencing of the 16S rRNA gene  
111 and liquid chromatography-mass spectrometry (LC-MS), respectively. We have used a  
112 Multi-Omics Factor Analysis (MOFA) [25, 26] machine learning model to  
113 systematically integrate data on caecal microbiota and the host metabolome  
114 sampled during an anticoccidial vaccine trial, investigating host microbe-associated  
115 signatures that can predict chicken health status and vaccine efficacy.

116

117 **RESULTS**

118 **Caecal pathology and parasite load *post-Eimeria* challenge demonstrates efficacy of**  
119 **a candidate yeast-vectored anticoccidial vaccine**

120 We previously evaluated the efficacy of an experimental *S. cerevisiae*-vectored  
121 anticoccidial vaccine using readouts of gut pathology (caecal lesion scores: 0-4),  
122 parasite replication (quantitative PCR of caecal tissue) and chicken performance  
123 (body weight gain, BWG) following oral challenge with 15,000 sporulated oocysts of  
124 *E. tenella* [10]. Briefly, lesion scores at 6 dpi were lower in vaccinated chickens  
125 compared to unvaccinated controls (V-C vs UV-C; p<0.001; Figure 1A). Parasite  
126 replication measured by qPCR as parasite genomes per host genome was also lower  
127 in vaccinated chickens at 6 dpi (p<0.001; Figure 1B). In contrast, BWG was not  
128 significantly different at 6 dpi (Figure 1C) although it was by 10 dpi [10].

129 In the present study, the level of *E. tenella* replication at 6 dpi was confirmed by  
130 quantification of *Eimeria* mitochondrial 16S rRNA amplicon reads in NGS microbiome  
131 data from caecal tissue and contents (Figures 1D and 1E). Comparison of all three *E.*  
132 *tenella* replication measures revealed a significant association with lesion score  
133 severity (qPCR ratio: r=0.89, NGS reads of caecal contents: r=0.8, NGS reads of caecal  
134 tissue: r=0.63; all p<0.001; Figure 1F). For comparison, 10 dpi unvaccinated and  
135 challenged chickens (UV-C10) considered to be recovering from infection also  
136 showed a significant reduction in gut pathology and *Eimeria* load compared to all  
137 infected subjects at 6 dpi (p<0.001; Figures 1A and 1E).

138

139 **Gut pathology and parasite load correlate with changes in gut microbiota**

140 The composition of enteric microbial populations can reflect the health status of  
141 micro-ecosystems in the gastrointestinal (GI) tract. We performed 16S amplicon  
142 sequencing from caecal contents and tissues collected from the same individuals to  
143 characterize gut microbiota composition, with no significant differences in beta  
144 diversity detected between sample types (caecal tissue compared to caecal contents;  
145 PERMANOVA test  $R^2=0.026$ , p=0.052) (Figure S1A). Comparison between caecal  
146 contents and tissue found 62.7-73.6% of microbiota composition to be shared  
147 (Figures S1B). Microbial populations enriched in caecal contents included  
148 *Lactobacillus mucosae*, *Lactobacillus salivarius*, *Paludicola psychrotolerans*,  
149 *Kineothrix alysoides*, *Anaerostipes butyraticus*, and [*Clostridium*]  
150 *polysaccharolyticum*; while microbial populations of *Anaerotruncus colihominis* (KTU  
151 13) and *Flavonifractor plautii* (KTU 14) were enriched in caecal tissues (i.e. UV-C, MV-  
152 C, and V-C) (Figure S1C).

153

154 Principal coordinates analysis (PCoA) based on Bray-Curtis dissimilarity

155 measurements showed that the caecal contents microbiota composition of  
156 unchallenged versus all challenged groups were distinct from each other (6 dpi) along  
157 the PCoA1 axis (31.15% of observed variation) (Figure 2). A PERMANOVA test  
158 confirmed significant differences in microbiota ( $R^2=0.33$ ,  $p=0.001$ ) (Figure 2A) and  
159 there were significant correlations with caecal lesion scores ( $|r|=0.73$ ,  $p<0.001$ ),  
160 parasite load in caecal tissues (qPCR ratio:  $|r|=0.76$ ,  $p<0.001$ ) and caecal contents  
161 (NGS reads:  $|r|=0.67$ ,  $p<0.001$ ) (Figure 2B-D).

162

163 On average a low alpha diversity index of microbial richness was found in all  
164 chickens across all groups ( $71.64\pm14.21$ ) compared to a previous study by Hay et al.  
165 (2023) ( $493.13\pm201.60$ , re-analysed using the same pipeline used in the present  
166 study)[27]. This disparity may be due to requirement for broad-spectrum  
167 enrofloxacin treatment during this trial (Figure 2E). Comparison between the groups  
168 revealed a higher richness index in all challenged groups 6 dpi compared to the  
169 unvaccinated, unchallenged group (UV-UC), although the difference was not  
170 statistically significant. The dominant phyla were *Firmicutes*, followed by  
171 *Proteobacteria* in all chickens (combined, accounting for more than 98%) (Figure 2F);  
172 however, *Proteobacteria* were reduced in UV-UC chickens (4.83% comparing to  
173 13.5%/26.65%/22.36% in other groups). *Actinobacteria* were enriched in both mock  
174 and true vaccinated groups (1.55% and 1.35%, respectively), dominated by genus  
175 *Bifidobacterium* (1.50% and 1.30%, respectively). Since the lesion scores and *Eimeria*  
176 loads were significantly correlated with the PCoA1 axis of beta diversity, 36  
177 associated taxa enriched in challenged chickens were identified by Pearson's  
178 correlation analysis ( $|r|\geq 0.4$ , FDR  $< 0.1$ ), including *Escherichia coli*, *Clostridium*  
179 *difficile*, *C. innocuum*, and *Proteus mirabilis* (Figure 2G).

180

## 181 **Metabolomes reflect the molecular alterations of host physiology responses in 182 health, infection, and recovery**

183 Caecal tissue metabolomic profiling was performed for the same chickens as  
184 described above using samples collected in parallel with those used for microbiome  
185 sequencing analysis to characterize host physiological responses. An untargeted  
186 metabolomics approach was applied for screening metabolites within the tissues.  
187 Based on Euclidean distance measurements, PCoA of caecal tissue metabolome  
188 profiles showed a similar pattern to the caecal microbiota with unchallenged and  
189 challenged individuals differentiated along the PCoA1 axis (52.73% of observed  
190 variation) (Figure 3). The recovering (UV-C10) group displayed a broad but  
191 intermediate metabolome profile to that of 6 dpi challenged chickens and uninfected  
192 chickens and this group was also differentiated along the PCoA2 axis (9.57%). Host

193 metabolome profiles correlated with caecal lesion scores ( $|r|=0.83$ ,  $p<0.001$ ) and  
194 *Eimeria* loads (qPCR ratio:  $|r|=0.73$ ,  $p<0.001$ ; NGS reads of caecal contents:  $|r|=0.83$ ,  
195  $p<0.001$ ; NGS reads of caecal tissues:  $|r|=0.68$ ,  $p<0.001$ ) (Figure 3B-C). Among 1,180  
196 metabolites belonging to the 10 categories that were detected from all chickens  
197 (including partially characterized and uncharacterized; Figure 3D), 954 metabolites  
198 were either negatively (606, non-infection-associated) or positively (348, infection-  
199 associated) correlated with pathophysiology changes (lesion scores and *Eimeria*  
200 loads; significant negative correlation with PCo1 in Figure 3A by Pearson's correlation  
201 analysis, FDR < 0.1; Figure 3E). In more detail, xenobiotics, cofactors and vitamins,  
202 especially vitamin Bs, were characterized as non-infection-associated metabolites  
203 (Figure S2A and Table S2); while lipids, especially the sphingolipids, nucleotides, and  
204 carbohydrates, were characterized as infection-associated metabolites (Figure S2B  
205 and Table S2).

206

#### 207 **Multi-omics factor analysis reveals covariation patterns of disease status**

208 Using multi-omics factor analysis (MOFA), integration of parallel caecal tissue  
209 and content microbiomes with host tissue metabolome data showed concordant  
210 responses that associated with gut pathology and parasite load. Host-microbe  
211 intercorrelated features were assessed between microbial and metabolite features  
212 using Spearman's correlation. A total of 151 KTUs and 767 metabolites were  
213 significantly associated (FDR<0.05), resulting in a MOFA model that contained 15  
214 representative factors. The factors were decomposed and ordered by the fraction of  
215 significant associations they contributed to the major variances (Figure 4A). The first  
216 two MOFA factors explained the most variance that differentiated the unchallenged,  
217 challenged, and recovering groups on the MOFA scatter plot (Figure 4B). In addition,  
218 covariate (phenotype) correlation analysis demonstrated that the first two MOFA  
219 factors were associated with the majority of the covariates (Figure 4C) where factor 1  
220 (FA1) was particularly associated with covariates related to infection ( $r < -0.6$ ) and  
221 factor 2 (FA2) was associated with BWG ( $r=0.56$ ); associations not identified in  
222 correlations of single omics analyses.

223

224 Multi-omics networks can contextualize the multiple types of microbiome  
225 disruption associated with various biological molecules found in different health  
226 statuses [28]. Additionally, a network's hotspot molecular features (hubs and  
227 clusters) can highlight targets to be followed-up. Here, we conducted network  
228 analyses downstream of MOFA to explore biomarkers that might associate with  
229 anticoccidial vaccination. Network analyses for the MOFA factors showed sub-  
230 structures (clusters of intercorrelated features) that were enriched in each MOFA

231 factor (Figure 4D-E). Three clusters were identified from FA1 components; two  
232 associated with *Eimeria* challenged chickens (including unvaccinated, vaccinated and  
233 recovering groups) (FA1-C1 and C3 in Figure 4D), whilst the third associated  
234 exclusively with unchallenged chickens (FA1-C2 in Figure 4D). Additionally, cluster 1  
235 in the FA2 network demonstrated associations between unchallenged/recovering  
236 groups and the 6 dpi-challenged group (FA2-C1 in Figure 4E). Clustered components  
237 from the FA1 and FA2 networks associated with non-challenge and recovery were  
238 enriched by vitamin B and derivatives (e.g., pyridoxine, riboflavin, nicotinate  
239 derivatives), short-chain fatty acids (e.g., butyrate/isobutyrate and valerate), and  
240 short-chain fatty acid-producing bacteria (e.g., *Caproicibacter fermentans* and  
241 *Ruminococcoides bili*). Itaconate, an antipathogenic organic acid was enriched in  
242 recovering chickens. In contrast, uremic toxin (e.g., p-cresol sulfate), the long-chain  
243 fatty acids and derivatives (e.g., 14–18C fatty acids and glycerophospholipids (GPs),  
244 glycerophosphocholine (GPC), phosphoethanolamine (PE) derivatives), metabolites  
245 of fatty acid metabolism (eicosenoylcarnitine and docosadienoylcarnitine), and gut  
246 pathogens (e.g., *Clostridium difficile* and *C. innocuum*) and commensal bacteria (e.g.,  
247 *Escherichia coli*, *Clostridium bolteae*, and *Fecalibacterium prausnitzii*), were enriched  
248 in post-*Eimeria* challenged associated clusters of both networks (Figure S3).

249

## 250 **MOFA models discover potential signature markers of host response to challenge 251 after vaccination**

252 While highlighting the covariation patterns of disease status, the MOFA model  
253 constructed using data from all samples did not reveal factors specifically associated  
254 with unvaccinated-challenged and vaccinated-challenged (mock and true vaccines)  
255 chickens. A more focused MOFA model was performed on all 6 dpi challenged groups  
256 to identify signature markers after vaccination. In the second model, the first four  
257 MOFA factors contributed to the major variation of the data and the fraction of  
258 significant associations (Figure 5A). Interestingly, the phenotypic and pathological  
259 covariates were more closely associated with FA4 and FA11 (e.g., lesion score  
260 severity was more associated with FA4 than other FA;  $r=-0.57$ ). Vaccine treatment  
261 conditions (Yeast: treating with yeast vectors or not; Vaccination: treating with the  
262 true vaccine or not) were negatively associated with FA4 and FA11, and the parasite  
263 load (qPCR ratio) was associated with both FAs ( $r=-0.59$  and  $-0.37$ ) (Figure 5C).  
264 Comparison of FA4 and FA11 using a scatter plot demonstrated that FA4 clearly  
265 distinguished the treatment condition of yeast vectors between unvaccinated (UV-C)  
266 and vaccinated groups (MV-C and V-C). FA11 showed a different trend between the  
267 mock vaccine group (MV-C) and the true vaccine group (V-C) (Figure 5B). Using  
268 network analysis, the signature features of various sphingolipids (e.g. sphingosine,

269 sphingomyelin) and *Ruminococcus lactaris* were clustered from both FAs and  
270 enriched in most vaccinated subjects; whereas the long-chain fatty acids (e.g.,  
271 linoleoyl-arachidonoyl-glycerol and oleoyl-oleoyl-glycerol) were enriched in  
272 unvaccinated-unchallenged chickens (Figure 5D-E, and Figure S4).  
273

274 **DISCUSSION**

275 An experimental yeast-vectored anticoccidial vaccine has recently been described as  
276 a step towards improved control of *Eimeria* species such as *E. tenella*, which cause  
277 coccidiosis in chickens [10]. Small-scale studies under commercial conditions found  
278 that vaccination could partially control the direct consequences of live parasite  
279 challenge, reducing parasite replication and its associated enteric pathology, while  
280 protecting performance (BWG and feed conversion ratio). In the present study, we  
281 have assessed the impact of vaccination on indirect consequences of *Eimeria*  
282 infection including microbial dysbiosis and metabolic disruption.

283

284 Using 16S rDNA amplicon sequencing from caecal contents and caecal tissue of  
285 experimentally vaccinated and challenged chickens (specific pathogen-free sourced),  
286 the microbiota richness was lower than in a previous farm study (Hay *et al.* 2023),  
287 likely due to the necessary enrofloxacin medication in the early rearing period to  
288 control an outbreak of colibacillosis. Indeed, it is well described that antibiotic  
289 treatment severely impacts on microbiome composition and richness, but recovering  
290 to its normal composition after stopping the treatment. While this was unexpected,  
291 such treatments are common under field conditions. Microbiota richness is also  
292 expected to be higher in populations of mixed breed chickens reared in the field  
293 under varied husbandry regimes than under the controlled conditions used in the  
294 present study. Comparison between caecal contents and tissues found no significant  
295 differences in alpha diversity ( $p=0.87$ ) and beta diversity ( $p=0.052$ ) (Figure S1). Only  
296 *Anaerotruncus (A.) colihominis* and *Flavonifractor (F.) plautii* were consistently  
297 enriched in caecal tissue samples across multiple groups (UV-UC, MV-C, and V-C),  
298 indicating their association with the intestinal mucosal environment. *A. colihominis*,  
299 originally isolated from mouse colonic mucosa by the Leibniz Institute DSMZ, has  
300 been detected in the intestinal lumen and stool samples of patients with  
301 bacteraemia and colorectal cancer, suggesting a potential broader role in gut  
302 dysbiosis and pathology [29, 30]. Similarly, *F. plautii*, known for its ability to degrade  
303 flavonoids and potentially mucins, was isolated by Levine *et al.* from mammalian  
304 intestinal mucosa [31]. Its presence in these tissue samples underscores its  
305 importance in gut health and disease [31, 32]. Based on our findings, investigation of  
306 caecal contents alone appears to be sufficient to investigate total gut microbiota  
307 because these reflect the primary condition of the intestinal ecosystem.

308

309 *Eimeria* infection is known to predispose chickens to diseases such as necrotic  
310 enteritis, caused by *C. perfringens* [33], and can disrupt enteric microbial populations  
311 leading to dysbiosis [21]. We anticipated that beta diversity, but not alpha diversity,

312 would change following *Eimeria* challenge. However, although average richness was  
313 lower in unchallenged chickens, the difference was not statistically significant (Figure  
314 2). Comparison of bacterial abundance between infected and non-infected chickens  
315 revealed increased Gammaproteobacteria and pathogenic *Clostridia* in *Eimeria*-  
316 challenged chickens. Common gastrointestinal pathogens, including *Escherichia* (*E.*)  
317 *coli*, *Clostridium* (*C.*) *difficile*, *Enterococcus* (*E.*) *cecorum*, *Proteus mirabilis*, and  
318 *Clostridium* (*C.*) *innocuum*, were also in higher abundance (Figure 2G) suggesting  
319 significant dysbiosis occurred following *Eimeria* challenge infection. It is notable that  
320 some strains of *E. caecorum* have been reported to cause high morbidity and  
321 mortality in broiler chickens [34]. Additionally, *C. difficile* and *C. innocuum* can cause  
322 antibiotic-associated diarrhea and have shown vancomycin resistance [35, 36],  
323 suggesting that a compromised gut environment may facilitate colonization by  
324 antibiotic-resistant strains; this condition mirrors the mechanism of human  
325 pseudomembranous colitis, which arises due to the overgrowth of *C. difficile*  
326 following extensive antibiotic usage. *Eimeria* infection can alter the gut  
327 microenvironment by increasing intestinal permeability and inflammation [37],  
328 thereby interacting bidirectionally with the gut microbiota. Consequences of enteric  
329 dysbiosis include immune dysregulation causing gut-related disorders such as  
330 allergies, inflammatory bowel disease (IBD) and autoimmune disorders [38-40]. Thus,  
331 *Eimeria* challenge is likely to activate a synergistic response between the host's  
332 physiology and the commensal gut microbiota. Intestinal infections can decrease  
333 oxygen levels and lead to chronic tissue and mucosal hypoxia with dysregulation of  
334 activation of hypoxia-inducible factors (HIFs) and NF- $\kappa$ B, exacerbating inflammation  
335 and injury of intestinal tissues [41, 42]. The metabolic environment of the mucosa is  
336 also altered during inflammation since the Enterobacteriaceae require terminal  
337 electron acceptors from the mucosa for anaerobic respiration and blooming [43, 44].  
338 Inflammatory cells release ROS and RNS, forming  $\text{NO}_3^-$  as a terminal electron  
339 acceptor for Gammaproteobacteria growth via denitrification [43, 45-51].  
340  
341 In all *Eimeria*-challenged groups (UV-C, MV-C, V-C) the gut microbiota composition  
342 was similar (Figure 2A). However, yeast treatment groups (MV-C and V-C) showed a  
343 significant increase in *E. coli* abundance, nearly double in UV-C and over six times  
344 higher in UV-UC. While harmful *E. coli* may increase due to infection, it is possible  
345 that some protective *E. coli* strains that can stimulate an innate immune mechanism  
346 [52] and produce vitamins [53, 54] colonize after the reversion of dysbiosis. Notably,  
347 *Bifidobacterium*, a common lactic acid-producing probiotic, was present in both yeast  
348 treatment groups, irrespective of *Eimeria* antigen expression. In addition,  
349 Lactobacillales family bacteria (*Enterococcus*, *Lactobacillus*, *Pediococcus*) were

350 enriched in both non-infected and yeast treatment groups, with *Lactobacillus* and  
351 *Pediococcus* being particularly higher in non-infected groups. This enrichment  
352 suggests a beneficial modulation of the gut microbiota. Yeasts and lactic acid-  
353 producing bacteria, often found together in nature [55], decrease pH value during  
354 fermentation creating an unfavourable environment for some pathogens [56, 57].  
355

356 We used a multi-omics integrative tool, MOFA, to infer how the host metabolome  
357 interacts with gut microbes under a range of vaccination and *Eimeria* infection  
358 conditions. MOFA modelling confirmed that metabolites involved in fatty acid  
359 metabolism and β-oxidation pathways were altered by *Eimeria* infection [23].  
360 Inflammation and oxidative stress induced by *Eimeria* invasion and subsequent  
361 pathology increase demand for metabolites involved in fatty acid metabolism [58].  
362 The model found that carnitine derivatives such as eicosenolylcarnitine and  
363 docosadienolylcarnitine, intermediate metabolites involved in fatty acid metabolism,  
364 were enriched in the *Eimeria* challenged groups (challenge groups compared to non-  
365 challenge and recovering groups; factor 2 of MOFA model 1). In addition, p-cresol  
366 sulfate (pCS), a uremic toxin formed by gut microbial fermentation of tyrosine [59,  
367 60], was also enriched in all challenged groups, especially in unvaccinated,  
368 challenged chickens (factor 1 of MOFA model 1). The main producer of pCS, *C.*  
369 *difficile*, a significant cause of diarrhoea during microbial ecosystem collapse, was  
370 also identified (factor 1 of MOFA model 1) [61, 62]. These findings link both layers of  
371 omics and prove evidence that *Eimeria* infection causes dysbiosis.  
372

373 Since the first MOFA model (the full model with all groups of the trial) could not  
374 distinguish an effect of vaccination among the challenged, non-challenged and  
375 recovering groups, a second MOFA model was used to explore latent grouping  
376 among vaccinated and non-vaccinated chickens. We found sphingolipids, including  
377 sphingosine, sphingomyelin, and sphingoinositol, were significant factors associated  
378 with vaccination. Sphingolipids are required in cell membrane structures of  
379 eukaryotes (especially the Schwann's cell, which surrounds the neuron axon) and  
380 some prokaryotes [63], as well as essential signalling molecules of inflammatory,  
381 immunity, cell autophagy, growth, and survival regulations [63-67]. Brown et al.  
382 (2019) indicated that the microbe-derived sphingolipids (especially from *Bacteroides*)  
383 are negatively correlated with gastrointestinal inflammation (i.e., inflammatory  
384 bowel disease) and maintaining homeostasis and symbiosis of gut microbiota [68].  
385 This finding supports the efficacy of the yeast-based oral anti-coccidiosis vaccine and  
386 indicates that the vaccine can alter the symbiosis status of gut microbiota. However,  
387 only a few reads of *Bacteroides* were detected from yeast-based vaccine-treated

388 samples and non-*Eimeria*-challenged samples (including from caecal tissues and  
389 contents), possibly due to the early antibiotic treatment of all study subjects. It  
390 implies that the microbial anti-inflammatory sphingolipids could be produced via  
391 other microbial species in the chicken gut microbiota, then act as a signal of anti-  
392 coccidiosis for the further applications.

393

394 In conclusion, using MOFA machine learning to integrate evaluation of potential  
395 interactions between the enteric microbiome and host metabolism provided a  
396 mechanistic insight into effects of anticoccidial vaccination and *Eimeria* challenge. In  
397 the present study, we identified Gamma-proteobacteria, *p*-cresol sulfate,  
398 *Bifidobacterium*, carnitine-derived metabolites and sphingolipids as host-microbe-  
399 associated biomarkers that vary between healthy, infected, vaccinated and/or  
400 recovering chickens, providing insights into potential strategies for controlling,  
401 treating and preventing coccidiosis. As we look to the future, the findings of this  
402 study are poised to contribute to the advancement of precision agriculture,  
403 particularly in enhancing poultry health management and the development of novel  
404 interventions against coccidiosis.

405

406 **MATERIALS AND METHODS**

407 **Ethics statement**

408 The animal experiments in this study were approved by the Royal Veterinary College  
409 (RVC) Animal Welfare Ethical Review Body (AWERB) and performed under the  
410 Animals in Scientific Procedures Act 1986 (ASPA) with a UK Home Office Licence.

411

412 **Study animals, metadata measurement and study design**

413 Cobb500 broiler chickens were purchased from P. D. Hook (Hatcherries) Ltd. (Cote,  
414 UK) at day of hatch. All chickens received enrofloxacin (Baytril®, Bayer, Leverkusen,  
415 Germany, 10 mg Kg<sup>-1</sup>) from days 16 to 18 of the trial due to an outbreak of  
416 colibacillosis. Feeding and vaccination treatments were as described in a previous  
417 study (Study 4 in [10] ). Briefly, four groups of ten chickens were sampled from a  
418 larger vaccination study six days post *E. tenella* challenge including (1) unvaccinated,  
419 challenged (UV-C), (2) unvaccinated, unchallenged (UV-UC), (3) mock vaccinated,  
420 challenged (MV-C), and (4) vaccinated, challenged (V-C) groups. A fifth group of eight  
421 unvaccinated, challenged chickens were sampled ten days post challenge (UV-C10;  
422 **Table S1**). Mock and experimental vaccines were administered by oral inoculation in  
423 100 µl phosphate buffer saline (PBS) every 3-4 days from day 7 of age (five doses per  
424 chicken in total). Group 3 (MV-C) was vaccinated using a mock vaccine including *S.*  
425 *cerevisiae* EBY100 strain (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA)  
426 containing the empty yeast display plasmid vector pYD1 (Invitrogen). Group 4 (V-C)  
427 was vaccinated at the same timepoints by oral inoculation of an experimental  
428 trivalent formulation of *S. cerevisiae*-vectored recombinant vaccine using pYD1 to  
429 separately express each of three *E. tenella* antigens including EtAMA1 ectodomain  
430 [11], EtIMP1 [12] and EtMIC3 [13]. The vaccine design and administration procedures  
431 were as described previously [10]. Groups 1, 3, 4 and 5 were challenged by oral  
432 inoculation with 15,000 sporulated *E. tenella* Houghton strain oocysts at 21 days of  
433 age. Challenge oocysts were prepared and inoculated following established protocols  
434 [69]. Caeca (paired) were collected immediately post-mortem at six or ten days post  
435 infection (dpi, Groups 1-4, and 5, respectively). The severity of infection was  
436 assessed using the Johnson and Reid scoring system [70]. Overall production  
437 performance was defined by Body Weight Gain (BWG) between 0 and 6 dpi. Parasite  
438 replication was measured using quantitative PCR for parasite genomes per host  
439 genome [10].

440

441 **DNA extraction and 16S amplicon sequencing**

442 Bacterial genomic DNA was extracted separately from caecal tissue (~100 mg) and  
443 caecal contents (~200 mg) using a QIAamp Fast DNA Stool Mini kit (QIAGEN, Valencia,

444 CA, USA) following the manufacturer's pathogen detection protocol. 16S amplicon  
445 library preparation followed the Illumina 16S Metagenomic Sequencing Library  
446 Preparation guidelines [71]. The 16S ribosomal RNA (rRNA) gene V3–V4  
447 hypervariable regions were amplified by PCR with the adapter overhang primers  
448 341F (5' -TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGC CCTACGGGNGGCWGCAG-  
449 3') and 805R (5' -GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  
450 GACTACHVGGGTATCTAATCC-3') for 25 cycles. Indices and Illumina sequencing  
451 adapters were attached using the Nextera XT Index Kit with 8 cycles of a second  
452 amplification reaction. The final PCR products were purified using AMPure XP beads  
453 (Beckman Coulter, Brea, CA, USA). The amplicon DNA concentration was measured  
454 using Qubit dsDNA HS and BR Assay Kits (Thermo Fisher Scientific, Waltham, MA,  
455 USA). Library quality was determined using the Agilent Technologies 2100  
456 Bioanalyzer system with a DNA-1000 chip. Eighty-eight samples representing caecal  
457 tissues from all chickens in Groups 1-5 (n=48) and caecal contents from all chickens in  
458 Groups 1-4 (n=40) were pooled with equal molality. The 16S amplicon libraries were  
459 sequenced using a 301 bp paired-end (301bp x 2) approach on an Illumina MiSeq  
460 platform using V3 chemistry.

461

## 462 **Bioinformatic processing and microbiota analyses**

463 The Illumina MiSeq platform generated a total of 22,525,182 paired-end sequences.  
464 Sequences were cleaned by sequence length  $\geq$  300bp using Trimmomatic [72]. The  
465 16S amplicon sequences were processed using the Quantitative Insights Into  
466 Microbial Ecology 2 (QIIME 2) pipeline (version 2019.10) [73]. Primer sequences were  
467 removed by Cutadapt (version 1.15) [74]. Trimmed sequences were truncated at  
468 240 bp (forward) and 210 (reverse) and denoised using the DADA2 algorithm [75].  
469 Amplicon sequence variants (ASVs) were obtained via the denoising process with  
470 quality filtering and chimera removal. A k-mer based re-clustering algorithm 'KTU'  
471 [76] was subsequently applied to assemble ASVs into optimal biological taxonomic  
472 units (KTUs). KTUs taxonomy was assigned by comparison with the SILVA SSU  
473 reference nr99 (v138) [77, 78] and NCBI 16S RefSeq (retrieved 10<sup>th</sup> Feb. 2022)  
474 databases using the kaxonomy function of the KTU R-package. Eukaryotic organelle  
475 16S sequences (identified as *Eimeria*) were extracted and used for supplementary  
476 parasite load quantification; non-prokaryotic and unassigned KTUs were removed  
477 from the microbiota dataset. The 309 KTU microbiota dataset was rarefied at the  
478 minimum read counts among samples (10,034 reads) after removing twelve samples  
479 with shallow sequence depth (< 10,000 reads).

480

481 Microbiota analyses were conducted and visualized using the Microbiome Analysis R

482 code (MARco) [79], Community Ecology ‘vegan’ [80], and Pretty Heatmap  
483 (pheatmap) [81] packages in R (version 4.0.1) [82]. The ANOVA test with Tukey HSD  
484 *post-hoc* multiple comparison test or Kruskal-Wallis test with Dunn’s *post-hoc*  
485 multiple comparison test were used for parametric and non-parametric statistical  
486 analyses of group comparisons with a significance level of  $\alpha = 0.05$ , and the P values  
487 were adjusted with a false discovery rate (FDR). Alpha diversity indices were  
488 estimated by richness. Beta diversity of microbial communities was measured by  
489 Bray-Curtis dissimilarity using principal coordinates analysis (PCoA), and  
490 heterogeneity was tested using ADONIS and ANOSIM tests.

491

## 492 **Metabolome profiling**

493 Untargeted metabolome profiling of caecal tissues was performed by Metabolon  
494 (NC, USA) using their vendor protocol. Briefly, all samples were deproteinized by  
495 dissociating small molecules bound to protein or trapped in the precipitated protein  
496 matrix. To recover chemically diverse metabolites, methanol was used for protein  
497 precipitation under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000)  
498 followed by centrifugation. The extract was aliquoted into five fractions: two for  
499 analysis by separate reverse phase (RP)/UPLC-MS/MS methods with positive ion  
500 mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with negative  
501 ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and  
502 one sample was reserved as backup. Samples were placed briefly on a TurboVap®  
503 (Zymark) to remove the organic solvent. The sample extracts were stored overnight  
504 under nitrogen before preparation for analysis.

505

506 All methods used Waters ACQUITY ultra-performance liquid chromatography (UPLC)  
507 and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer  
508 interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass  
509 analyzer operated at 35,000 mass resolution. Each sample extract was dried then  
510 reconstituted in solvents compatible to each of the four methods. Each  
511 reconstitution solvent contained a series of standards at fixed concentrations to  
512 ensure injection and chromatographic consistency. One aliquot was analyzed using  
513 acidic positive ion conditions, chromatographically optimized for more hydrophilic  
514 compounds. The extract was gradient eluted from a C18 column (Waters UPLC BEH  
515 C18-2.1x100 mm, 1.7  $\mu$ m) using water and methanol, containing 0.05%  
516 perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). Another aliquot was also  
517 analyzed using acidic positive ion conditions; however, it was chromatographically  
518 optimized for more hydrophobic compounds. The extract was gradient eluted from  
519 the same afore mentioned C18 column using methanol, acetonitrile, water, 0.05%

520 PFPA and 0.01% FA and was operated at an overall higher organic content. Another  
521 aliquot was analyzed using basic negative ion optimized conditions using a separate  
522 dedicated C18 column. The basic extracts were gradient eluted from the column  
523 using methanol and water, however with 6.5mM ammonium bicarbonate at pH 8.  
524 The fourth aliquot was analyzed via negative ionization following elution from a HILIC  
525 column (Waters UPLC BEH Amide 2.1x150 mm, 1.7  $\mu$ m) using a gradient consisting of  
526 water and acetonitrile with 10mM ammonium formate, pH 10.8. The MS analysis  
527 alternated between MS and data-dependent MS<sup>n</sup> scans using dynamic exclusion. The  
528 scan range varied slightly between methods, but covered 70-1000 m/z.  
529

530 Raw data were extracted, peak-identified and QC processed by Metabolon's in-house  
531 systems. Compounds were identified by comparison to library entries of purified  
532 standards or recurrent unknown entities. The in-house library was built and  
533 maintained by Metabolon, and contained more than 3,300 commercially available  
534 purified standard compounds with the information of retention time/index (RI), mass  
535 to charge ratio ( $m/z$ ), and chromatographic data (including MS/MS spectral data).  
536 Compound identification was based on the following criteria: retention index within a  
537 narrow RI window of the proposed identification, accurate mass match to the library  
538 +/- 10 ppm, and the MS/MS forward and reverse scores between the experimental  
539 data and authentic standards.

540  
541 A subset of 1,180 metabolites was detected from the untargeted metabolomics screen.  
542 Each metabolite's peak area (i.e. total ion counts, integrated area-under-the-curve)  
543 was median-scaled to normalize. The missing values were then imputed with the  
544 observed minimum of each metabolite. Since the metabolomic data were typically  
545 close to log-normal distribution, the normalized-imputed data were transformed using  
546 the natural log for subsequent analyses.

547  
548 **Multi-Omics Factor Analysis (MOFA) model for microbiota and metabolome  
549 integrative analysis**

550 MOFA model fittings were performed to integrate multi-omics data modalities based  
551 on an unsupervised machine learning model formulated in a probabilistic Bayesian  
552 framework. The 16S rRNA amplicons of caecal tissue and content, and host caecal  
553 metabolome were the separate data modalities in this study. In order to make all  
554 omics data comparable, the amplicon abundance was centered log-ratio transformed  
555 using the 'clr' function of the compositions R-package. Spearman's correlation (FDR  
556 <0.05) was implemented to select associated features from the omics datasets [83].  
557 Downstream characterization was performed by variance decomposition, detecting

558 the fraction of significant associations between the features and each factor using  
559 Pearson's correlation (FDR < 0.1), and correlation of phenotype covariates. A sub-  
560 grouped MOFA model fitting was performed on all 6 dpi challenged groups. A  
561 network analysis for identifying sub-structures of MOFA factors was performed with  
562 the R package igraph47 [84]. An adjacency matrix based on Spearman's correlation  
563 coefficients of intercorrelated features was constructed from a MOFA factor of  
564 interest; these coefficients were also used for assessing length of edges on the  
565 network. The latter was conducted with the fast greedy modularity optimization  
566 algorithm [85] to identify clusters in the network.

567

568 **SUPPORTING INFORMATION**

569 **Figure S1. Comparisons of microbiota profiles between chicken caecal contents and**  
570 **caecal tissues.** (A) Beta diversity analysis with the PERMANOVA test demonstrated  
571 no significant differences between caecal contents and caecal tissues ( $p=0.052$ ). (B)  
572 Venn diagrams show 62.7-73.6% microbiota composition shared between caecal  
573 contents and tissues in four study groups (UV-C, UV-UC, MV-C, and V-C). (C)  
574 Differential abundance ( $p<0.05$  by DESeq2 test) of microbes between caecal contents  
575 and caecal tissues in four study groups, respectively.

576

577 **Figure S2. Lesion score and *Eimeria* load correlated metabolites.** (A) Categories of  
578 non-infection-associated metabolites. (B) Categories of infection-associated  
579 metabolites.

580

581 **Figure S3. Details of subnetworks from the MOFA model.** Microbial and  
582 metabolomic features of each cluster (C1-C3) in FA1(Figure 4D) and FA2(Figure 4E)—  
583 the abundance of microbial and metabolomic features among groups were  
584 presented by heatmap. The left columns were annotated by sample sources (C:  
585 caecal content microbiome; T: caecal tissue microbiome; M: caecal tissue  
586 metabolite).

587

588 **Figure S4. Details of subnetworks from 6dpi -challenged MOFA model.** Microbial  
589 and metabolomic features of each cluster (C1-C2) in FA4(Figure 5D) and FA11(Figure  
590 5E)—the abundance of microbial and metabolomic features among groups were  
591 presented by heatmap. The left columns were annotated by sample sources (C:  
592 caecal content microbiome; T: caecal tissue microbiome; M: caecal tissue  
593 metabolite).

594

595 **Table S1. Sample information of studying groups**

596

597 **Table S2. Infection-associated metabolites**

598

599 **DATA AVAILABILITY.**

600 The original data set presented in the study is publicly available. These data can be  
601 found at NCBI under BioProject accession number: PRJNA990995.

602

603 **ACKNOWLEDGEMENTS**

604 We thank Dr Meiyeh Jade Lu from the NGS Core, Academia Sinica, and Ms Yu-Tang  
605 Yang from the National Taiwan University College of Medicine for the technical  
606 consultancy of the NGS library construction. We gratefully acknowledge the support  
607 of the Houghton Trust Research Grants for funding this project.

608

609 **CONFLICT OF INTEREST**

610 The authors declare that there is no conflict of interest.

611


612 **AUTHORS' CONTRIBUTION**

613 Conceptualization: P-Y.L., D.X., F.M.T., and D.P.B. Performed experiment: P-Y.L., J.L.,  
614 F.S., J.J.O, and D.P.B. Data analysis: P-Y.L. Contributed data or analysis tools: F.S., D.W.,  
615 and O.G. Writing—original draft: P-Y.L. and D.X. Writing—review and editing: P-Y.L.,  
616 D.X., and D.P.B.

617

618

619 **FIGURES & TABLES**




620

621 **Figure 1. Summary of vaccine trial phenotypes assessed six days post infection (dpi)**  
622 **with 15,000 sporulated *Eimeria tenella* oocysts. (A) Caecal lesion scores, (B) parasite**  
623 **load represented as parasite genomes per host genome, determined using qPCR, (C)**  
624 **bodyweight gain from 0 to 6 dpi, (D and E) parasite load represented by *Eimeria***  
625 **mitochondrial 16S rRNA sequence reads in caecal contents and tissue, (F) association**  
626 **between caecal lesion score and parasite load measures. Panels A-C reanalysed from**  
627 **Soutter et al., 2022.**

628 Groups UV-C: unvaccinated, challenged, UV-UC: unvaccinated, unchallenged, MV-C:  
629 mock vaccinated, challenged, V-C vaccinated, challenged.


630



631

632 **Figure 2. Gut microbiota profiling and associations of gut pathology and parasite**  
 633 **loads.** (A) Principal coordinates analysis (based on Bray-Curtis distance) for beta  
 634 diversity of gut microbiota composition (caecal contents) among four groups of  
 635 chickens. (B) The correlation between microbiota composition and lesion scores. (C)-  
 636 (D) The correlations between microbiota composition and parasite loads, (C) based  
 637 on qPCR quantification of the ratio of *Eimeria* and host genes, (D) based on NGS  
 638 reads of *Eimeria* apicoplast 16S rRNA gene. (E) Alpha diversity (richness) of four  
 639 groups of chickens. (F) Relative abundance of gut microbiota composition at the  
 640 phylum level. (G) Gut pathology and parasite load associated microbes (Pearson's  $r >$   
 641 0.4 or  $< -0.4$ , FDR-adjusted  $p < 0.05$ ) extracted from PCoA1 of panel (A).  
 642 Groups UV-C: unvaccinated, challenged, UV-UC: unvaccinated, unchallenged, MV-C:  
 643 mock vaccinated, challenged, V-C vaccinated, challenged.

644




645

646 **Figure 3. Chicken caecal tissue metabolome profiling and associations of gut**  
647 **pathology and parasite loads.** (A) Principal coordinates analysis (based on Euclidean  
648 distance) for chicken caecal tissue metabolome composition among five groups of  
649 chickens. (B) The correlation between metabolome composition and lesion scores.  
650 (C) The correlation between metabolome composition and parasite loads, based on  
651 NGS reads of *Eimeria* apicoplast 16S rRNA gene. (D) Compositions and categories of  
652 the metabolome of five groups of chickens. (E) Gut pathology and parasite load  
653 associated metabolites (Pearson's  $r > 0.4$  or  $< -0.4$ , FDR-adjusted  $p < 0.05$ ) extracted  
654 from PCoA1 of panel (A).

655 Groups UV-C: unvaccinated, challenged, UV-UC: unvaccinated, unchallenged, MV-C:  
656 mock vaccinated, challenged, V-C vaccinated, challenged, UV-C10: unvaccinated,  
657 challenged, 10 days post-infection.

658




659

660 **Figure 4. MOFA model for all trial groups and downstream signature marker**  
661 **identification by network analysis.** (A) Bar plots showing the fraction of significant  
662 associations between the features of each microbiome or metabolome modality and  
663 each factor. The stacked bars interpret whether the variance-explained values are  
664 driven by a strong change in a small number of features or by a moderate effect  
665 across a large range of features. (B) Scatterplot of factor 1 (x axis) versus factor 2 (y  
666 axis). Each dot represents a sample, colored by the trial group. (C) The correlation  
667 heatmap of MOFA factors and phenotypes (Eimeria.c: NGS read-based *Eimeria* load  
668 in caecal contents; Eimeria.t: NGS read-based *Eimeria* load in caecal tissues; qPCR:  
669 qPCR-based *Eimeria* load in caecal tissues; Infection: infection condition- infected or  
670 non-infected; Yeast: yeast vector exposure or not; Vaccination: vaccination condition-


671 vaccinated or non-vaccinated). (D)-(E) Network analysis and visualization for the  
672 features from (D) factor 1 and (E) factor 2. Thumbnail legends present the regions of  
673 subnetworks.

674




676 **Figure 5. MOFA model for challenged 6dpi chickens and downstream signature**  
677 **marker identification by network analysis.** (A) Bar plots showing the fraction of  
678 significant associations between the features of each microbiome or metabolome  
679 modality and each factor. The stacked bars interpret whether the variance-explained  
680 values are driven by a strong change in a small number of features or by a moderate  
681 effect across a large range of features. (B) Scatterplot of factor 4 (x axis) versus factor  
682 11 (y axis). Each dot represents a sample, colored by the trial group. (C) The

683 correlation heatmap of MOFA factors and phenotypes (Eimeria.c: NGS read-based  
684 *Eimeria* load in caecal contents; Eimeria.t: NGS read-based *Eimeria* load in caecal  
685 tissues; qPCR: qPCR-based *Eimeria* load in caecal tissues; Yeast: yeast vector  
686 exposure or not; Vaccination: vaccination condition- vaccinated or non-vaccinated).  
687 (D)-(E) Network analysis and visualization for the features from (D) factor 4 and (E)  
688 factor 11. Thumbnail legends present the regions of subnetworks.  
689




690  
691 **Figure S1. Comparisons of microbiota profiles between chicken caecal contents and**  
692 **caecal tissues. (A)** Beta diversity analysis with the PERMANOVA test demonstrated

693 no significant differences between caecal contents and caecal tissues ( $p=0.052$ ). (B)  
694 Venn diagrams show 62.7-73.6% microbiota composition shared between caecal  
695 contents and tissues in four study groups (UV-C, UV-UC, MV-C, and V-C). (C)  
696 Differential abundance ( $p<0.05$  by DESeq2 test) of microbes between caecal contents  
697 and caecal tissues in four study groups, respectively.  
698




699  
700 **Figure S2. Lesion score and *Eimeria* load correlated metabolites.** (A) Categories of  
701 non-infection-associated metabolites. (B) Categories of infection-associated  
702 metabolites.  
703



704

705 **Figure S3. Details of subnetworks from the MOFA model.** Microbial and  
706 metabolomic features of each cluster (C1-C3) in FA1 (Figure 4D) and FA2 (Figure 4E)—  
707 the abundance of microbial and metabolomic features among groups were  
708 presented by heatmap. The left columns were annotated by sample sources (C):

709 caecal content microbiome; T: caecal tissue microbiome; M: caecal tissue  
 710 metabolite).  
 711



712  
 713 **Figure S4. Details of subnetworks from 6dpi-challenged MOFA model.** Microbial  
 714 and metabolomic features of each cluster (C1-C2) in FA4 (Figure 5D) and FA11 (Figure  
 715 5E)—the abundance of microbial and metabolomic features among groups were  
 716 presented by heatmap. The left columns were annotated by sample sources (C:  
 717 caecal content microbiome; T: caecal tissue microbiome; M: caecal tissue  
 718 metabolite).  
 719

**Table S1. Sample information of studying groups**

Groups	# of samples	Description	Content ID	Tissue ID
UV-C	10	Unvaccinated, challenged, 6 dpi	C1	T1

UV-UC	10	Unvaccinated, unchallenged, 6 dpi	C2	T2
MV-C	10	Mock vaccinated, challenged, 6 dpi	C3	T3
V-C	10	Vaccinated, challenged, 6 dpi	C4	T4
UV-C10	8	Unvaccinated, challenged, 10 dpi	-	T5

---

720

721

722 **REFERENCES**

- 723 1. Blake DP, Knox J, Dehaeck B, Huntington B, Rathinam T, Ravipati V, et al. Re-  
724 calculating the cost of coccidiosis in chickens. *Vet Res.* 2020;51(1):115. Epub  
725 2020/09/16. doi: 10.1186/s13567-020-00837-2. PubMed PMID: 32928271; PubMed  
726 Central PMCID: PMCPMC7488756.
- 727 2. Rothwell L, Young JR, Zoorob R, Whittaker CA, Hesketh P, Archer A, et al. Cloning  
728 and characterization of chicken IL-10 and its role in the immune response to *Eimeria*  
729 *maxima*. *J Immunol.* 2004;173(4):2675-82. Epub 2004/08/06. doi:  
730 10.4049/jimmunol.173.4.2675. PubMed PMID: 15294985.
- 731 3. Laurent F, Mancassola R, Lacroix S, Menezes R, Naciri M. Analysis of chicken  
732 mucosal immune response to *Eimeria tenella* and *Eimeria maxima* infection by  
733 quantitative reverse transcription-PCR. *Infect Immun.* 2001;69(4):2527-34. Epub  
734 2001/03/20. doi: 10.1128/IAI.69.4.2527-2534.2001. PubMed PMID: 11254616;  
735 PubMed Central PMCID: PMCPMC98188.
- 736 4. Hong YH, Lillehoj HS, Lee SH, Dalloul RA, Lillehoj EP. Analysis of chicken cytokine  
737 and chemokine gene expression following *Eimeria acervulina* and *Eimeria tenella*  
738 infections. *Vet Immunol Immunopathol.* 2006;114(3-4):209-23. Epub 2006/09/26.  
739 doi: 10.1016/j.vetimm.2006.07.007. PubMed PMID: 16996141.
- 740 5. Wu Z, Hu T, Rothwell L, Vervelde L, Kaiser P, Boulton K, et al. Analysis of the  
741 function of IL-10 in chickens using specific neutralising antibodies and a sensitive  
742 capture ELISA. *Dev Comp Immunol.* 2016;63:206-12. Epub 2016/04/25. doi:  
743 10.1016/j.dci.2016.04.016. PubMed PMID: 27108075; PubMed Central PMCID:  
744 PMCPMC4947970.
- 745 6. Peek HW, Landman WJ. Coccidiosis in poultry: anticoccidial products, vaccines  
746 and other prevention strategies. *Vet Q.* 2011;31(3):143-61. Epub 2011/10/28. doi:  
747 10.1080/01652176.2011.605247. PubMed PMID: 22029884.
- 748 7. Blake DP, Tomley FM. Securing poultry production from the ever-present  
749 *Eimeria* challenge. *Trends Parasitol.* 2014;30(1):12-9. Epub 2013/11/19. doi:  
750 10.1016/j.pt.2013.10.003. PubMed PMID: 24238797.
- 751 8. Chapman HD, Jeffers TK. Vaccination of chickens against coccidiosis ameliorates  
752 drug resistance in commercial poultry production. *Int J Parasitol Drugs Drug Resist.*  
753 2014;4(3):214-7. Epub 20141025. doi: 10.1016/j.ijpddr.2014.10.002. PubMed PMID:  
754 25516830; PubMed Central PMCID: PMCPMC4266793.
- 755 9. Venkatas J, Adeleke MA. A review of *Eimeria* antigen identification for the  
756 development of novel anticoccidial vaccines. *Parasitol Res.* 2019;118(6):1701-10.  
757 Epub 20190508. doi: 10.1007/s00436-019-06338-2. PubMed PMID: 31065831.
- 758 10. Soutter F, Werling D, Nolan M, Kuster T, Attree E, Marugan-Hernandez V, et al. A  
759 Novel Whole Yeast-Based Subunit Oral Vaccine Against *Eimeria tenella* in Chickens.

760 Front Immunol. 2022;13:809711. Epub 2022/02/22. doi:  
761 10.3389/fimmu.2022.809711. PubMed PMID: 35185896; PubMed Central PMCID:  
762 PMCPMC8848252.

763 11. Blake DP, Clark EL, Macdonald SE, Thenmozhi V, Kundu K, Garg R, et al.  
764 Population, genetic, and antigenic diversity of the apicomplexan *Eimeria tenella* and  
765 their relevance to vaccine development. Proc Natl Acad Sci U S A.  
766 2015;112(38):E5343-50. Epub 20150909. doi: 10.1073/pnas.1506468112. PubMed  
767 PMID: 26354122; PubMed Central PMCID: PMCPMC4586875.

768 12. Kundu K, Garg R, Kumar S, Mandal M, Tomley FM, Blake DP, et al. Humoral and  
769 cytokine response elicited during immunisation with recombinant Immune Mapped  
770 protein-1 (EtIMP-1) and oocysts of *Eimeria tenella*. Vet Parasitol. 2017;244:44-53.  
771 Epub 20170724. doi: 10.1016/j.vetpar.2017.07.025. PubMed PMID: 28917316.

772 13. Labbe M, de Venevelles P, Girard-Miguich F, Bourdieu C, Guillaume A, Pery P.  
773 *Eimeria tenella* microneme protein EtMIC3: identification, localisation and role in  
774 host cell infection. Mol Biochem Parasitol. 2005;140(1):43-53. doi:  
775 10.1016/j.molbiopara.2004.12.002. PubMed PMID: 15694485.

776 14. Bortoluzzi C, Barbosa JGM, Pereira R, Fagundes NS, Rafael JM, Menten JFM.  
777 Autolyzed Yeast (*Saccharomyces cerevisiae*) Supplementation Improves Performance  
778 While Modulating the Intestinal Immune-System and Microbiology of Broiler  
779 Chickens. Frontiers in Sustainable Food Systems. 2018;2. doi:  
780 10.3389/fsufs.2018.00085.

781 15. Luquetti BC, Furlan RL, Alarcon MFF, Macari M. *Saccharomyces cerevisiae* cell  
782 wall dietary supplementation on the performance and intestinal mucosa  
783 development and integrity of broiler chickens vaccinated against coccidiosis. Revista  
784 Brasileira de Ciência Avícola. 2012;14(2):89-95. doi: 10.1590/s1516-  
785 635x2012000200002.

786 16. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria  
787 as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol.  
788 2013;24(2):160-8. Epub 2012/09/04. doi: 10.1016/j.copbio.2012.08.005. PubMed  
789 PMID: 22940212.

790 17. Sannino DR, Dobson AJ, Edwards K, Angert ER, Buchon N. The *Drosophila*  
791 *melanogaster* Gut Microbiota Provisions Thiamine to Its Host. mBio. 2018;9(2). Epub  
792 2018/03/08. doi: 10.1128/mBio.00155-18. PubMed PMID: 29511074; PubMed  
793 Central PMCID: PMCPMC5845000.

794 18. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity.  
795 Nature. 2016;535(7610):65-74. Epub 2016/07/08. doi: 10.1038/nature18847.  
796 PubMed PMID: 27383981.

797 19. Ximenez C, Torres J. Development of Microbiota in Infants and its Role in

798 Maturation of Gut Mucosa and Immune System. *Arch Med Res.* 2017;48(8):666-80.

799 Epub 2017/12/05. doi: 10.1016/j.arcmed.2017.11.007. PubMed PMID: 29198451.

800 20. Jebessa E, Guo L, Chen X, Bello SF, Cai B, Girma M, et al. Influence of *Eimeria*  
801 *maxima* coccidia infection on gut microbiome diversity and composition of the  
802 jejunum and cecum of indigenous chicken. *Front Immunol.* 2022;13:994224. Epub  
803 2022/09/05. doi: 10.3389/fimmu.2022.994224. PubMed PMID: 36131927; PubMed  
804 Central PMCID: PMCPMC9483182.

805 21. Macdonald SE, Nolan MJ, Harman K, Boulton K, Hume DA, Tomley FM, et al.  
806 Effects of *Eimeria tenella* infection on chicken caecal microbiome diversity, exploring  
807 variation associated with severity of pathology. *PLoS One.* 2017;12(9):e0184890.  
808 Epub 2017/09/22. doi: 10.1371/journal.pone.0184890. PubMed PMID: 28934262;  
809 PubMed Central PMCID: PMCPMC5608234.

810 22. Moore RJ. Necrotic enteritis predisposing factors in broiler chickens. *Avian*  
811 *Pathol.* 2016;45(3):275-81. Epub 2016/03/02. doi: 10.1080/03079457.2016.1150587.  
812 PubMed PMID: 26926926.

813 23. Aggrey SE, Milfort MC, Fuller AL, Yuan J, Rekaya R. Effect of host genotype and  
814 *Eimeria acervulina* infection on the metabolome of meat-type chickens. *PLoS One.*  
815 2019;14(10):e0223417. Epub 2019/10/17. doi: 10.1371/journal.pone.0223417.  
816 PubMed PMID: 31618222; PubMed Central PMCID: PMCPMC6795442.

817 24. Li S, Sullivan NL, Roush N, Yu T, Banton S, Maddur MS, et al. Metabolic  
818 Phenotypes of Response to Vaccination in Humans. *Cell.* 2017;169(5):862-77 e17.  
819 Epub 2017/05/16. doi: 10.1016/j.cell.2017.04.026. PubMed PMID: 28502771;  
820 PubMed Central PMCID: PMCPMC5711477.

821 25. Haak BW, Argelaguet R, Kinsella CM, Kullberg RFJ, Lankelma JM, Deijs M, et al.  
822 Integrative Transkingdom Analysis of the Gut Microbiome in Antibiotic Perturbation  
823 and Critical Illness. *mSystems.* 2021;6(2). Epub 2021/03/18. doi:  
824 10.1128/mSystems.01148-20. PubMed PMID: 33727397; PubMed Central PMCID:  
825 PMCPMC8546997.

826 26. Argelaguet R, Velten B, Arnol D, Dietrich S, Zenz T, Marioni JC, et al. Multi-Omics  
827 Factor Analysis-a framework for unsupervised integration of multi-omics data sets.  
828 *Mol Syst Biol.* 2018;14(6):e8124. Epub 2018/06/22. doi: 10.15252/msb.20178124.  
829 PubMed PMID: 29925568; PubMed Central PMCID: PMCPMC6010767.

830 27. Hay MC, Hinsu AT, Koringa PG, Pandit RJ, Liu P-Y, Parekh MJ, et al. Chicken caecal  
831 enterotypes in indigenous Kadaknath and commercial Cobb chicken lines are  
832 associated with *Campylobacter* abundance and influenced by farming practices.  
833 *Frontiers in Microbiomes.* 2023;2. doi: 10.3389/frmbi.2023.1301609.

834 28. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon  
835 TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel

836 diseases. *Nature*. 2019;569(7758):655-62. Epub 2019/05/31. doi: 10.1038/s41586-  
837 019-1237-9. PubMed PMID: 31142855; PubMed Central PMCID: PMCPMC6650278.

838 29. Lau SK, Woo PC, Woo GK, Fung AM, Ngan AH, Song Y, et al. Bacteraemia caused  
839 by *Anaerotruncus colihominis* and emended description of the species. *J Clin Pathol*.  
840 2006;59(7):748-52. Epub 20060207. doi: 10.1136/jcp.2005.031773. PubMed PMID:  
841 16467163; PubMed Central PMCID: PMCPMC1860411.

842 30. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-  
843 associated microbiota in patients with colorectal cancer. *PLoS One*.  
844 2012;7(6):e39743. Epub 20120628. doi: 10.1371/journal.pone.0039743. PubMed  
845 PMID: 22761885; PubMed Central PMCID: PMCPMC3386193.

846 31. Levine UY, Looft T, Allen HK, Stanton TB. Butyrate-producing bacteria, including  
847 mucin degraders, from the swine intestinal tract. *Appl Environ Microbiol*.  
848 2013;79(12):3879-81. Epub 20130412. doi: 10.1128/AEM.00589-13. PubMed PMID:  
849 23584773; PubMed Central PMCID: PMCPMC3675948.

850 32. Rodriguez-Castano GP, Rey FE, Caro-Quintero A, Acosta-Gonzalez A. Gut-derived  
851 Flavonifractor species variants are differentially enriched during in vitro incubation  
852 with quercetin. *PLoS One*. 2020;15(12):e0227724. Epub 20201202. doi:  
853 10.1371/journal.pone.0227724. PubMed PMID: 33264299; PubMed Central PMCID:  
854 PMCPMC7710108.

855 33. Stanley D, Wu SB, Rodgers N, Swick RA, Moore RJ. Differential responses of cecal  
856 microbiota to fishmeal, *Eimeria* and *Clostridium perfringens* in a necrotic enteritis  
857 challenge model in chickens. *PLoS One*. 2014;9(8):e104739. Epub 2014/08/29. doi:  
858 10.1371/journal.pone.0104739. PubMed PMID: 25167074; PubMed Central PMCID:  
859 PMCPMC4148237.

860 34. Jung A, Chen LR, Suyemoto MM, Barnes HJ, Borst LB. A Review of *Enterococcus*  
861 *cecorum* Infection in Poultry. *Avian Dis*. 2018;62(3):261-71. doi: 10.1637/11825-  
862 030618-Review.1. PubMed PMID: 30339512.

863 35. Chen YC, Kuo YC, Chen MC, Zhang YD, Chen CL, Le PH, et al. Case-Control Study  
864 of *Clostridium innocuum* Infection, Taiwan. *Emerg Infect Dis*. 2022;28(3):599-607.  
865 doi: 10.3201/eid2803.204421. PubMed PMID: 35195517; PubMed Central PMCID:  
866 PMCPMC8888209.

867 36. Chia JH, Wu TS, Wu TL, Chen CL, Chuang CH, Su LH, et al. *Clostridium innocuum*  
868 is a vancomycin-resistant pathogen that may cause antibiotic-associated diarrhoea.  
869 *Clin Microbiol Infect*. 2018;24(11):1195-9. Epub 20180217. doi:  
870 10.1016/j.cmi.2018.02.015. PubMed PMID: 29458157.

871 37. Pham HHS, Matsubayashi M, Tsuji N, Hatabu T. Relationship between *Eimeria*  
872 *tenella* associated-early clinical signs and molecular changes in the intestinal barrier  
873 function. *Vet Immunol Immunopathol*. 2021;240:110321. Epub 20210828. doi:

874 10.1016/j.vetimm.2021.110321. PubMed PMID: 34520968.

875 38. Arrieta MC, Finlay BB. The commensal microbiota drives immune homeostasis.

876 Front Immunol. 2012;3:33. Epub 2012/05/09. doi: 10.3389/fimmu.2012.00033.

877 PubMed PMID: 22566917; PubMed Central PMCID: PMCPMC3341987.

878 39. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease.

879 Semin Immunopathol. 2015;37(1):47-55. Epub 2014/11/26. doi: 10.1007/s00281-

880 014-0454-4. PubMed PMID: 25420450; PubMed Central PMCID: PMCPMC4281375.

881 40. Sartor RB. Microbial influences in inflammatory bowel diseases.

882 Gastroenterology. 2008;134(2):577-94. Epub 2008/02/05. doi:

883 10.1053/j.gastro.2007.11.059. PubMed PMID: 18242222.

884 41. Singhal R, Shah YM. Oxygen battle in the gut: Hypoxia and hypoxia-inducible

885 factors in metabolic and inflammatory responses in the intestine. J Biol Chem.

886 2020;295(30):10493-505. Epub 2020/06/07. doi: 10.1074/jbc.REV120.011188.

887 PubMed PMID: 32503843; PubMed Central PMCID: PMCPMC7383395.

888 42. Van Welden S, Selfridge AC, Hindryckx P. Intestinal hypoxia and hypoxia-induced

889 signalling as therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol.

890 2017;14(10):596-611. Epub 2017/08/31. doi: 10.1038/nrgastro.2017.101. PubMed

891 PMID: 28853446.

892 43. Winter SE, Baumler AJ. Dysbiosis in the inflamed intestine: chance favors the

893 prepared microbe. Gut Microbes. 2014;5(1):71-3. Epub 2014/03/19. doi:

894 10.4161/gmic.27129. PubMed PMID: 24637596; PubMed Central PMCID:

895 PMCPMC4049941.

896 44. Winter SE, Baumler AJ. Why related bacterial species bloom simultaneously in

897 the gut: principles underlying the 'Like will to like' concept. Cell Microbiol.

898 2014;16(2):179-84. Epub 2013/11/30. doi: 10.1111/cmi.12245. PubMed PMID:

899 24286560; PubMed Central PMCID: PMCPMC4013256.

900 45. Bliska JB, van der Velden AW. *Salmonella* "sops" up a preferred electron receptor

901 in the inflamed intestine. mBio. 2012;3(4):e00226-12. Epub 2012/08/16. doi:

902 10.1128/mBio.00226-12. PubMed PMID: 22893385; PubMed Central PMCID:

903 PMCPMC3419527.

904 46. Lopez CA, Rivera-Chavez F, Byndloss MX, Baumler AJ. The Periplasmic Nitrate

905 Reductase NapABC Supports Luminal Growth of *Salmonella enterica* Serovar

906 Typhimurium during Colitis. Infect Immun. 2015;83(9):3470-8. Epub 2015/06/24. doi:

907 10.1128/IAI.00351-15. PubMed PMID: 26099579; PubMed Central PMCID:

908 PMCPMC4534643.

909 47. Lopez CA, Winter SE, Rivera-Chavez F, Xavier MN, Poon V, Nuccio SP, et al.

910 Phage-mediated acquisition of a type III secreted effector protein boosts growth of

911 *salmonella* by nitrate respiration. mBio. 2012;3(3). Epub 2012/06/14. doi:

912 10.1128/mBio.00143-12. PubMed PMID: 22691391; PubMed Central PMCID:  
913 PMCPMC3374392.

914 48. Rivera-Chavez F, Winter SE, Lopez CA, Xavier MN, Winter MG, Nuccio SP, et al.  
915 *Salmonella* uses energy taxis to benefit from intestinal inflammation. *PLoS Pathog.*  
916 2013;9(4):e1003267. Epub 2013/05/03. doi: 10.1371/journal.ppat.1003267. PubMed  
917 PMID: 23637594; PubMed Central PMCID: PMCPMC3630101.

918 49. Spees AM, Wangdi T, Lopez CA, Kingsbury DD, Xavier MN, Winter SE, et al.  
919 Streptomycin-induced inflammation enhances *Escherichia coli* gut colonization  
920 through nitrate respiration. *mBio.* 2013;4(4). Epub 2013/07/04. doi:  
921 10.1128/mBio.00430-13. PubMed PMID: 23820397; PubMed Central PMCID:  
922 PMCPMC3705454.

923 50. Vazquez-Torres A, Baumler AJ. Nitrate, nitrite and nitric oxide reductases: from  
924 the last universal common ancestor to modern bacterial pathogens. *Curr Opin  
925 Microbiol.* 2016;29:1-8. Epub 2015/10/02. doi: 10.1016/j.mib.2015.09.002. PubMed  
926 PMID: 26426528; PubMed Central PMCID: PMCPMC4930242.

927 51. Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM, et al.  
928 Host-derived nitrate boosts growth of *E. coli* in the inflamed gut. *Science.*  
929 2013;339(6120):708-11. Epub 2013/02/09. doi: 10.1126/science.1232467. PubMed  
930 PMID: 23393266; PubMed Central PMCID: PMCPMC4004111.

931 52. Ash C. The benefits of *Escherichia coli*. *Science Signaling.* 2015;8(401). doi:  
932 10.1126/scisignal.aad7728.

933 53. Lawrence JG, Roth JR. Evolution of coenzyme B12 synthesis among enteric  
934 bacteria: evidence for loss and reacquisition of a multigene complex. *Genetics.*  
935 1996;142(1):11-24. doi: 10.1093/genetics/142.1.11. PubMed PMID: 8770581;  
936 PubMed Central PMCID: PMCPMC1206939.

937 54. Bentley R, Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria.  
938 *Microbiol Rev.* 1982;46(3):241-80. doi: 10.1128/mr.46.3.241-280.1982. PubMed  
939 PMID: 6127606; PubMed Central PMCID: PMCPMC281544.

940 55. Alexander M. *Microbial Ecology*. London, United Kingdom: John Wiley & Sons,  
941 Inc.; 1971.

942 56. Narendranath NV, Power R. Relationship between pH and medium dissolved  
943 solids in terms of growth and metabolism of *lactobacilli* and *Saccharomyces*  
944 *cerevisiae* during ethanol production. *Appl Environ Microbiol.* 2005;71(5):2239-43.  
945 Epub 2005/05/05. doi: 10.1128/AEM.71.5.2239-2243.2005. PubMed PMID:  
946 15870306; PubMed Central PMCID: PMCPMC1087585.

947 57. Lund PA, De Biase D, Liran O, Scheler O, Mira NP, Cetecioglu Z, et al.  
948 Understanding How Microorganisms Respond to Acid pH Is Central to Their Control  
949 and Successful Exploitation. *Front Microbiol.* 2020;11:556140. Epub 2020/10/30. doi:

950 10.3389/fmicb.2020.556140. PubMed PMID: 33117305; PubMed Central PMCID:  
951 PMCPMC7553086.

952 58. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-  
953 hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med.*  
954 1991;11(1):81-128. Epub 1991/01/01. doi: 10.1016/0891-5849(91)90192-6. PubMed  
955 PMID: 1937131.

956 59. Meijers BK, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and  
957 CKD progression. *Nephrol Dial Transplant.* 2011;26(3):759-61. Epub 2011/02/24. doi:  
958 10.1093/ndt/gfq818. PubMed PMID: 21343587.

959 60. Smith EA, Macfarlane GT. Enumeration of human colonic bacteria producing  
960 phenolic and indolic compounds: effects of pH, carbohydrate availability and  
961 retention time on dissimilatory aromatic amino acid metabolism. *J Appl Bacteriol.*  
962 1996;81(3):288-302. Epub 1996/09/01. doi: 10.1111/j.1365-2672.1996.tb04331.x.  
963 PubMed PMID: 8810056.

964 61. Passmore IJ, Letertre MPM, Preston MD, Bianconi I, Harrison MA, Nasher F, et  
965 al. Para-cresol production by *Clostridium difficile* affects microbial diversity and  
966 membrane integrity of Gram-negative bacteria. *PLoS Pathog.* 2018;14(9):e1007191.  
967 Epub 2018/09/13. doi: 10.1371/journal.ppat.1007191. PubMed PMID: 30208103;  
968 PubMed Central PMCID: PMCPMC6135563.

969 62. Paroni R, Casati S, Dei Cas M, Bignotto M, Rubino FM, Ciuffreda P. Unambiguous  
970 Characterization of p-Cresyl Sulfate, a Protein-Bound Uremic Toxin, as Biomarker of  
971 Heart and Kidney Disease. *Molecules.* 2019;24(20). Epub 2019/10/18. doi:  
972 10.3390/molecules24203704. PubMed PMID: 31618977; PubMed Central PMCID:  
973 PMCPMC6832250.

974 63. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from  
975 sphingolipids. *Nat Rev Mol Cell Biol.* 2008;9(2):139-50. Epub 2008/01/25. doi:  
976 10.1038/nrm2329. PubMed PMID: 18216770.

977 64. Koberlin MS, Snijder B, Heinz LX, Baumann CL, Fauster A, Vladimer GI, et al. A  
978 Conserved Circular Network of Coregulated Lipids Modulates Innate Immune  
979 Responses. *Cell.* 2015;162(1):170-83. Epub 2015/06/23. doi:  
980 10.1016/j.cell.2015.05.051. PubMed PMID: 26095250; PubMed Central PMCID:  
981 PMCPMC4523684.

982 65. Merrill AH, Jr., Carman GM. Introduction to Thematic Minireview Series: Novel  
983 Bioactive Sphingolipids. *J Biol Chem.* 2015;290(25):15362-4. Epub 2015/05/08. doi:  
984 10.1074/jbc.R115.663708. PubMed PMID: 25947376; PubMed Central PMCID:  
985 PMCPMC4505448.

986 66. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in  
987 immunity. *Nat Rev Immunol.* 2011;11(6):403-15. Epub 2011/05/07. doi:

988 10.1038/nri2974. PubMed PMID: 21546914; PubMed Central PMCID:  
989 PMCPMC3368251.

990 67. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease.  
991 *Nature*. 2014;510(7503):58-67. Epub 2014/06/06. doi: 10.1038/nature13475.  
992 PubMed PMID: 24899305; PubMed Central PMCID: PMCPMC4320971.

993 68. Brown EM, Ke X, Hitchcock D, Jeanfavre S, Avila-Pacheco J, Nakata T, et al.  
994 *Bacteroides-Derived Sphingolipids Are Critical for Maintaining Intestinal Homeostasis*  
995 and *Symbiosis*. *Cell Host Microbe*. 2019;25(5):668-80 e7. Epub 2019/05/10. doi:  
996 10.1016/j.chom.2019.04.002. PubMed PMID: 31071294; PubMed Central PMCID:  
997 PMCPMC6544385.

998 69. Pastor-Fernandez I, Pegg E, Macdonald SE, Tomley FM, Blake DP, Marugan-  
999 Hernandez V. *Laboratory Growth and Genetic Manipulation of Eimeria tenella*. *Curr*  
1000 *Protoc Microbiol*. 2019;53(1):e81. Epub 20190227. doi: 10.1002/cpmc.81. PubMed  
1001 PMID: 30811108.

1002 70. Johnson J, Reid WM. *Anticoccidial drugs: lesion scoring techniques in battery*  
1003 *and floor-pen experiments with chickens*. *Exp Parasitol*. 1970;28(1):30-6. doi:  
1004 10.1016/0014-4894(70)90063-9. PubMed PMID: 5459870.

1005 71. Illumina. *Illumina 16S metagenomic sequencing library preparation* (Illumina  
1006 Technical Note 15044223 Rev. A) 2013 [cited 2018 2018/10]. Available from:  
1007 [http://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry\\_documentation/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf](http://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_documentation/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf).

1008 72. Bolger AM, Lohse M, Usadel B. *Trimmomatic: a flexible trimmer for Illumina*  
1009 *sequence data*. *Bioinformatics*. 2014;30(15):2114-20. Epub 20140401. doi:  
1010 10.1093/bioinformatics/btu170. PubMed PMID: 24695404; PubMed Central PMCID:  
1011 PMCPMC4103590.

1012 73. Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, et al.  
1013 *Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME*  
1014 *2's q2-feature-classifier plugin*. *Microbiome*. 2018;6(1):90. Epub 2018/05/19. doi:  
1015 10.1186/s40168-018-0470-z. PubMed PMID: 29773078; PubMed Central PMCID:  
1016 PMCPMC5956843.

1017 74. Martin M. *Cutadapt removes adapter sequences from high-throughput*  
1018 *sequencing reads*. *EMBnetjournal*. 2011;17(1):10. doi: 10.14806/ej.17.1.200.

1019 75. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. *DADA2: High-resolution sample inference from Illumina amplicon data*. *Nat Methods*.  
1020 2016;13(7):581-3. Epub 2016/05/24. doi: 10.1038/nmeth.3869. PubMed PMID:  
1021 27214047; PubMed Central PMCID: PMCPMC4927377.

1022 76. Liu PY, Yang SH, Yang SY. *KTU: K-mer Taxonomic Units improve the biological*

1026 relevance of amplicon sequence variant microbiota data. Methods in Ecology and  
1027 Evolution. 2022;13(3):560-8. doi: 10.1111/2041-210x.13758. PubMed PMID:  
1028 WOS:000717949300001.

1029 77. Quast C, Pruesse E, Yilmaz P, Gerken J, Schneidman T, Yarza P, et al. The SILVA  
1030 ribosomal RNA gene database project: improved data processing and web-based  
1031 tools. Nucleic Acids Res. 2013;41(Database issue):D590-6. Epub 2012/11/30. doi:  
1032 10.1093/nar/gks1219. PubMed PMID: 23193283; PubMed Central PMCID:  
1033 PMCPMC3531112.

1034 78. Yilmaz P, Parfrey LW, Yarza P, Gerken J, Pruesse E, Quast C, et al. The SILVA and  
1035 "All-species Living Tree Project (LTP)" taxonomic frameworks. Nucleic Acids Research.  
1036 2014;42(D1):D643-D8. doi: 10.1093/nar/gkt1209. PubMed PMID:  
1037 WOS:000331139800094.

1038 79. Liu P-Y. poyliu/MARco: MARco: Microbiome Analysis RcodeDB (Version v1.0):  
1039 Zenodo; 2021. Available from: <http://doi.org/10.5281/zenodo.4589898>.

1040 80. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'Hara RB, et al.  
1041 vegan: community ecology package. R package version 2.3-1. Oulu, Finland2015.

1042 81. Kolde R. pheatmap: Pretty heatmaps. R package version 1.0.8. 2015.

1043 82. R Core Team. R: A language and environment for statistical computing. R  
1044 Foundation for Statistical Computing, Vienna, Austria; 2015.

1045 83. Dekkers KF, Sayols-Baixeras S, Baldanzi G, Nowak C, Hammar U, Nguyen D, et al.  
1046 An online atlas of human plasma metabolite signatures of gut microbiome  
1047 composition. medRxiv. 2021.

1048 84. Csardi G, Nepusz T. The igraph software package for complex network research.  
1049 InterJournal2006.

1050 85. Clauset A, Newman ME, Moore C. Finding community structure in very large  
1051 networks. Phys Rev E Stat Nonlin Soft Matter Phys. 2004;70(6 Pt 2):066111. doi:  
1052 10.1103/PhysRevE.70.066111. PubMed PMID: 15697438.

1053




Figure 1






Figure 2


A




B



C



D



E






Figure 3


A




B



C



D



E






Figure 4


A




B



C



D



E




Figure 5